Collectively, these results demonstrate that the combination of ATO and Dasatinib synergistically induces cell apoptosis in Ph+ ALL cell lines both by activating the IRE1‐JNK‐PUMA apoptosis pathway and abolishing the ATF4‐induced cell survival pathway. The gene discussed is ATF4; the disease is acute lymphoblastic leukemia.